📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-16 18:07
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
59 announcements match the current filters (relevance ≥ 5).
Alembic Pharma Receives USFDA EIR for Vadodara Bioequivalence Facility
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the USFDA, marking the formal closure of the inspection at its Bioequivalence Facility in Vadodara, Gujarat. The inspection took place between March 3, 2025, and March 7, 2025. This clears regulatory compliance uncertainty for the facility, supporting Alembic's ongoing clinical and bioequivalence studies required for its US generic pipeline. With Alembic generating TTM revenue of ₹7,550 Cr, smooth USFDA compliance across all sites is critical for its targeted 15-20 annual US product launches.
Confidence: HIGH
What changedThe USFDA has officially closed the audit of Alembic's Vadodara bioequivalence facility by issuing an Establishment Inspection Report (EIR).
Why it mattersBioequivalence studies from this facility feed directly into Alembic's US ANDA submissions, removing regulatory risk that could otherwise stall upcoming generic launches.
Inspection start date: 3rd March, 2025Inspection end date: 7th March, 2025Company TTM revenue context: Rs 7550 Cr
📅 Short termPositive sentiment for the stock as a clean regulatory report eliminates operational overhang on US pipeline submissions.
📈 Long termSupports the company's long-term pipeline execution and monetization of its complex chemistry and specialty generic investments.
Key Highlights
USFDA issued an Establishment Inspection Report (EIR) indicating inspection closure
Inspection conducted from 3rd March, 2025 to 7th March, 2025
Facility cleared is the Bioequivalence Facility located at Vadodara, Gujarat
Closure follows original intimation filed on 7th March, 2025
👀 What to Watch
Track the pace of new ANDA filings and product approvals in the US, as bioequivalence data integrity is essential for pipeline clearance.
Alembic Pharma Clears Unannounced USFDA Inspection at Vadodara with Zero Form 483 Observations
Alembic Pharmaceuticals has successfully completed an unannounced onsite USFDA Bioequivalence inspection at its Vadodara facility with zero Form 483 observations. The inspection took place between August 31, 2026, and September 10, 2026. A clean regulatory outcome at bioequivalence sites is vital for the company's US pipeline and planned 15-20 product launches in FY26. For a company generating Rs 7,550 Cr in TTM revenue, avoiding compliance disruptions protects ongoing US export growth.
Confidence: HIGH
What changedUSFDA concluded an unannounced onsite inspection of the Vadodara Bioequivalence facility with nil observations.
Why it mattersZero observations remove regulatory overhang for bioequivalence studies, ensuring uninterrupted ANDA filings and approvals for the US generic pipeline.
Form 483 observations: 0Inspection start date: 31st August, 2026Inspection end date: 10th September, 2026TTM Revenue (context): Rs 7550 Cr
📅 Short termPositive sentiment driver for the stock as unannounced audit risk has passed with zero observations.
📈 Long termStrengthens compliance standing with the USFDA, ensuring sustained new product approvals for Alembic's targeted expansion in the US market.
⚠ Risk flags
- Receipt of formal EIR pending from the USFDA
Key Highlights
Unannounced USFDA Bioequivalence inspection completed with 0 Form 483 observations
Inspection conducted over 11 days, from 31st August, 2026 to 10th September, 2026
Facility inspected is the Bioequivalence Facility located in Vadodara, Gujarat
Supports ongoing US filing pipeline and target of launching 15-20 products in the US in FY26
👀 What to Watch
Monitor upcoming quarterly US sales and receipt of the formal Establishment Inspection Report (EIR) from the USFDA.
26% Revenue Growth in Q1 FY27; US Generics Surges 49% YoY
Alembic Pharmaceuticals reported a strong Q1 FY27 with consolidated revenue growing 26% YoY to ₹2,150 cr, significantly exceeding the TTM quarterly average. The growth was led by a 49% surge in US Generics and a 33% increase in the API business. Consequently, management has upgraded its FY27 revenue growth guidance from low double-digits to the mid-teen range. While EBITDA grew 21% to ₹348 cr, margins (16%) remain under pressure due to ongoing investments in the US branded specialty platform and high R&D spending at 9% of revenue.
Confidence: HIGH
What changedAlembic has shifted from a conservative growth outlook to a more aggressive mid-teen guidance following a strong volume-led recovery in the US market.
Why it mattersThe strong performance in US Generics and API suggests that the company's heavy investments in new facilities and R&D are beginning to yield volume growth, though margin expansion is still pending the scale-up of specialty products.
Q1 Revenue: ₹2,150 crUS Revenue Growth: 49% YoYEBITDA Margin: 16%R&D Spend: ₹186 crGross Debt: ₹1,600 crQ1 Revenue vs TTM Revenue: 30.2%
📅 Short termThe stock may see positive momentum due to the guidance upgrade and robust top-line growth across all business segments.
📈 Long termLong-term value depends on the successful transition to complex generics and specialty therapies to offset pricing erosion in the base US generics business.
⚠ Risk flags
- Pricing pressure in US generic market
- Regulatory risks from USFDA inspections
- High working capital intensity leading to increased debt
Key Highlights
Consolidated revenue grew 26% YoY to ₹2,150 cr, driven by broad-based growth across all segments.
US Generics revenue increased 49% YoY, supported by 7 new product launches and volume growth.
R&D expenditure remained high at ₹186 cr, representing 9% of quarterly revenue.
Gross debt increased to ₹1,600 cr from March levels due to higher working capital and receivables.
Management upgraded FY27 overall revenue growth guidance to the mid-teen range.
👀 What to Watch
Investors should monitor the margin trajectory as the US Branded Specialty business scales up, which management expects will turn profit-contributory in coming quarters. Key metrics to watch include the utilization levels of the three new USFDA-approved facilities and the reduction of debt back toward 1x EBITDA.
Q1 FY27 Revenue up 26% to ₹2,150 Cr; US Formulation Business grows 49% YoY
Alembic Pharmaceuticals reported a strong start to FY27 with consolidated revenue growing 26% YoY to ₹2,150 Cr, representing approximately 30% of its TTM revenue. The growth was primarily driven by a 49% surge in the US Formulation business, which reached ₹778 Cr. While Profit After Tax (PAT) grew by a more modest 12% YoY to ₹173 Cr, the company maintained a healthy pre-R&D EBITDA margin of 24%. Operational momentum was supported by 7 new US launches and 10 ANDA approvals during the quarter.
Confidence: HIGH
What changedAlembic has reported a significant acceleration in its US business and API segments compared to the previous fiscal year, moving from a TTM revenue of ₹7,111 Cr to a quarterly run-rate exceeding ₹2,100 Cr.
Why it mattersThe 49% growth in the US market suggests that the company's strategy of launching complex generics and specialty therapies is gaining traction, potentially offsetting historical price erosion in the generic space.
Q1 FY27 Revenue: ₹2,150 CrQ1 Revenue vs TTM Revenue: 30.2%US Formulation Growth: 49%PAT Growth: 12%Pre-R&D EBITDA Margin: 24%
📅 Short termThe stock is likely to react positively to the strong revenue beat and the significant growth in the US and API segments.
📈 Long termStructural growth depends on the successful ramp-up of new facilities and the continued execution of the 15-20 planned US launches for FY27 to achieve better economies of scale.
⚠ Risk flags
- PAT growth lagging revenue growth
- Intense pricing pressure in US generics
- Regulatory risks associated with USFDA-approved facilities
Key Highlights
Consolidated revenue increased 26% YoY to ₹2,150 Cr for the quarter ended June 30, 2026.
US Formulation revenue grew 49% YoY to ₹778 Cr, supported by 7 new product launches.
API business delivered robust growth of 33% YoY, reaching ₹346 Cr.
EBITDA (pre-R&D) stood at ₹523 Cr with a margin of 24%.
Received 10 ANDA approvals during the quarter, strengthening the US pipeline.
👀 What to Watch
Investors should monitor the sustainability of the US growth momentum and the management's ability to convert high top-line growth into higher net profit margins, as PAT growth (12%) lagged revenue growth (26%). Watch for updates on the utilization levels of the three new USFDA-approved facilities.
26% Revenue Growth: Alembic Pharma Reports Q1 FY27 PAT of ₹173 Cr Driven by US Surge
Alembic Pharmaceuticals delivered a strong top-line performance in Q1 FY27, with consolidated revenue rising 26% YoY to ₹2,150 Cr. The growth was primarily fueled by a 49% jump in the US Formulation business (₹778 Cr) and a 33% increase in API sales (₹346 Cr). While EBITDA (pre-R&D) margins were healthy at 24%, Profit After Tax (PAT) grew at a slower pace of 12% YoY to ₹173 Cr. The company continues its US momentum with 7 new launches and 10 ANDA approvals during the quarter.
Confidence: HIGH
What changedAlembic has shown a significant acceleration in its US and API segments compared to the same quarter last year, moving past the sub-optimal capacity utilization issues noted in FY25.
Why it mattersThe strong US performance (49% growth) validates the company's strategy of launching specialty generics and suggests better absorption of overheads from its new manufacturing facilities.
Q1 FY27 Revenue: ₹2,150 CrYoY Revenue Growth: 26%US Formulation Growth: 49%Q1 PAT: ₹173 CrQ1 Revenue vs TTM Revenue: 30.2%EBITDA Margin (pre-R&D): 24%
📅 Short termThe stock is likely to react positively to the strong top-line beat and robust US sales figures in the coming weeks.
📈 Long termStructural growth depends on the successful ramp-up of new facilities and the ability to maintain margins despite US pricing pressure. The strong ANDA pipeline remains a long-term value driver.
⚠ Risk flags
- PAT growth lagging revenue growth
- Intense pricing pressure in US generics
- Regulatory risks associated with USFDA-approved sites
Key Highlights
Revenue from operations increased 26% YoY to ₹2,150 Cr, representing ~30% of TTM revenue.
US Formulation business grew 49% YoY to ₹778 Cr, supported by 7 new product launches.
API business recorded 33% growth reaching ₹346 Cr for the quarter.
EBITDA pre-R&D stood at ₹523 Cr with a margin of 24%.
Received 10 ANDA approvals during the quarter, strengthening the US pipeline.
👀 What to Watch
Investors should monitor the sustainability of the US growth momentum and check if the 12% PAT growth (which lagged the 26% revenue growth) indicates rising operational costs or R&D intensity. Watch for management commentary on the utilization levels of the three new USFDA-approved facilities.
26% Revenue Growth in Q1 FY27; US Formulations Surge 49% YoY
Alembic Pharmaceuticals reported a strong start to FY27 with quarterly revenue reaching ₹2,150 cr, a 26% YoY increase. The growth was primarily led by a 49% surge in US Formulation sales (₹778 cr) and a 33% rise in API business (₹346 cr). While EBITDA after R&D grew 21% to ₹344 cr, PAT growth was more moderate at 12% (₹173 cr) due to a 52% spike in material consumption costs and higher depreciation. The company maintained high R&D intensity at 9% of revenue to support its pipeline of 15+ planned US launches for the year.
Confidence: HIGH
What changedThe company has successfully pivoted to high growth in the US market and API segments, moving past the sub-optimal capacity utilization issues seen in FY25.
Why it mattersThe 49% US growth indicates that the heavy capital expenditure on new injectable and oncology facilities is finally translating into significant top-line contributions, which is critical for long-term margin expansion.
Q1 FY27 Revenue: ₹2,150 crRevenue vs TTM Revenue: 30.2%US Formulation Growth: 49% YoYR&D Spend: ₹186 crReported PAT: ₹173 crMaterial Consumption Increase: 52% YoY
📅 Short termThe stock is likely to react positively to the significant revenue beat and strong US performance, though the 52% jump in material costs may temper some enthusiasm regarding bottom-line margins.
📈 Long termStructural growth is visible as the company scales its complex generics and specialty portfolio. Sustained 10-11% growth and improved capacity utilization at new plants remain the key long-term drivers.
⚠ Risk flags
- High material cost inflation (52% YoY increase)
- Intense pricing pressure in the US generic market
- Regulatory risks associated with 9 USFDA-audited facilities
Key Highlights
US Formulation revenue grew 49% YoY to ₹7.78 bn, supported by 7 new product launches in the quarter.
API business recorded 33% YoY growth to ₹3.46 bn, driven by a strong order book and 3 new US DMF filings.
India Branded Business grew 7% YoY to ₹6.42 bn, with 5 flagship brands now exceeding ₹100 cr in annual sales.
R&D investment increased to ₹1.86 bn (9% of revenue) compared to ₹1.45 bn in the previous year.
Operating leverage improved with EBITDA margin (after R&D) reaching 16% vs 14% in the preceding quarter.
👀 What to Watch
Watch for the execution of the 15+ planned US product launches in FY27 and the margin trajectory as new facilities ramp up. Investors should also monitor USFDA inspection outcomes, particularly for the 9 manufacturing sites listed in the presentation.
₹2,150 Cr Revenue: Alembic Pharma Reports 25.6% YoY Revenue Growth in Q1 FY27
Alembic Pharmaceuticals reported a strong 25.6% YoY increase in consolidated revenue to ₹2,149.77 cr for the quarter ended June 30, 2026. Net profit grew by 13.6% YoY to ₹175.33 cr, supported by robust top-line momentum. However, operating margins faced pressure, contracting to 13.84% from 16.18% in the year-ago period. The company maintains a stable financial position with a debt-equity ratio of 0.24 and a net worth of ₹5,680.88 cr.
Confidence: HIGH
What changedAlembic has delivered a significant top-line beat compared to the previous year, though profitability growth is lagging revenue growth due to margin compression.
Why it mattersThe strong revenue growth validates the company's expansion strategy in the US and specialty therapies, but the margin drop highlights ongoing pricing pressure and higher operational costs in the generic drug segment.
Revenue (Q1 FY27): ₹2,149.77 crYoY Revenue Growth: 25.6%Net Profit (Q1 FY27): ₹175.33 crOperating Margin: 13.84%Debt-Equity Ratio: 0.24Revenue vs TTM Revenue: 30.2%
📅 Short termThe stock may see positive sentiment due to the strong 25%+ revenue growth, although the margin contraction might lead to some caution among analysts.
📈 Long termStructural growth depends on the company's ability to ramp up its new facilities and successfully launch complex generics to offset the 2-3% margin squeeze expected from US price erosion.
⚠ Risk flags
- Operating margin compression of 234 basis points YoY
- Intense pricing pressure in the US generic market
- Sub-optimal capacity utilization at new facilities impacting overhead absorption
Key Highlights
Consolidated revenue from operations grew 25.6% YoY to ₹2,149.77 cr from ₹1,710.72 cr.
Net profit after non-controlling interests rose 13.6% YoY to ₹175.33 cr.
Operating margin (EBITDA) stood at 13.84%, a decline from 16.18% in Q1 FY26.
Cost of materials consumed increased to ₹517.30 cr, representing 24% of revenue.
Debt-Equity ratio remained healthy at 0.24 times as of June 30, 2026.
👀 What to Watch
Investors should monitor the utilization levels of the three new USFDA-approved facilities to see if economies of scale can restore operating margins to the 15-16% range. Watch for updates on the planned 15-20 new product launches in the US market for FY27.
25.6% YoY Revenue Growth in Q1 FY27; Net Profit Rises 13% to Rs 175.3 Cr
Alembic Pharmaceuticals reported a strong start to FY27 with consolidated revenue growing 25.6% YoY to Rs 2,149.77 Cr. Net profit (attributable to owners) increased 13% YoY to Rs 175.33 Cr, supported by significant operating margin expansion from 13.84% to 16.18%. While revenue grew 16.3% sequentially, net profit saw a sequential decline from Rs 214.54 Cr in Q4 FY26. The company maintains a conservative leverage profile with a debt-equity ratio of 0.24.
Confidence: HIGH
What changedAlembic Pharma released its Q1 FY27 financial results, showing a significant jump in revenue and improved operating efficiency compared to the previous year.
Why it mattersThe strong revenue growth and margin expansion suggest that the company's strategy of launching new products in the US and focusing on specialty therapies is yielding results, despite sequential profit volatility.
Revenue (Q1 FY27): Rs 2,149.77 CrNet Profit (Q1 FY27): Rs 175.33 CrOperating Margin: 16.18%YoY Revenue Growth: 25.6%Debt-Equity Ratio: 0.24
📅 Short termThe stock may react positively to the strong YoY revenue growth and margin improvement, although the sequential decline in PAT might temper the enthusiasm.
📈 Long termThe structural improvement in margins and a robust revenue base of over Rs 2,100 Cr per quarter indicate a positive trajectory for the company's specialty generic focus.
⚠ Risk flags
- Sequential decline in net profit
- Intense pricing pressure in the US generic market
- Sub-optimal capacity utilization at new facilities impacting overheads
Key Highlights
Revenue from operations increased 25.6% YoY to Rs 2,149.77 Cr, representing ~30% of TTM revenue
Operating EBITDA margin expanded by 234 basis points YoY to 16.18%
Consolidated Net Profit for the quarter stood at Rs 175.33 Cr vs Rs 155.09 Cr in the same quarter last year
Earnings Per Share (EPS) for Q1 FY27 reported at Rs 8.80
Debt-Equity ratio remains stable at 0.24 as of June 30, 2026
👀 What to Watch
Investors should monitor the sustainability of the 16%+ operating margins and the utilization levels of the three new USFDA-approved facilities to see if they continue driving top-line growth.
Alembic Pharma Receives USFDA Approval for Prucalopride Tablets (Market Size $100M)
Alembic Pharmaceuticals has received final USFDA approval for Prucalopride Tablets (1 mg and 2 mg), a generic version of Motegrity used to treat chronic idiopathic constipation. The product addresses a US market estimated at $100 million for the 12 months ending March 2026. This approval is part of the company's strategy to launch 15-20 new products in the US market during FY26. While the addressable market is significant at approximately 11-12% of TTM revenue, actual revenue will depend on market share capture and generic pricing competition.
Confidence: HIGH
What changedAlembic has secured regulatory clearance to market a generic version of a $100 million gastrointestinal drug in the United States.
Why it mattersThis approval helps offset intense price erosion in the US generic market and contributes to the ramp-up of Alembic's three new USFDA-approved manufacturing facilities.
Estimated Market Size: US$ 100 millionCumulative Final Approvals: 225TTM Revenue: Rs 7111 CrMarket Size vs TTM Revenue: ~11.6%Total ANDA Approvals: 245
📅 Short termThe approval provides positive sentiment and validates the company's R&D pipeline, likely supporting the stock's recent recovery trend.
📈 Long termConsistent approvals are critical for Alembic to achieve its 10-11% growth target and improve ROCE (currently 12%) by utilizing its expanded manufacturing base.
⚠ Risk flags
- Intense pricing pressure in the US generic market
- Potential for 2-3% margin squeeze due to price erosion
- Execution risk in capturing market share from competitors
Key Highlights
Final USFDA approval received for Prucalopride Tablets in 1 mg and 2 mg strengths.
Estimated addressable US market size of US$ 100 million for the 12 months ending March 2026.
Cumulative USFDA approvals now stand at 245, including 225 final and 20 tentative approvals.
Product is therapeutically equivalent to the reference drug Motegrity by Takeda Pharmaceuticals.
Supports the company's FY26 target of launching 15-20 new products in the US market.
👀 What to Watch
Investors should track the commercial launch timeline and the company's ability to capture market share in the US. Monitor upcoming quarterly results for improvements in US business margins, which have been impacted by sub-optimal capacity utilization at new facilities.
$1.4 Billion Market Opportunity: Alembic Partner NATCO Receives Tentative USFDA Approval for Olaparib
Alembic Pharmaceuticals' partner, NATCO Pharma, has received tentative USFDA approval for Olaparib Tablets (100 mg and 150 mg), a generic version of AstraZeneca's Lynparza. The product targets a substantial U.S. market estimated at $1.4 billion for the 12 months ending March 2026. While Alembic will serve as the distributor in the U.S., the launch is currently pending the outcome of ongoing Para IV litigation. This approval brings Alembic's cumulative USFDA ANDA count to 244, including 20 tentative approvals.
Confidence: HIGH
What changedAlembic's partner received a tentative regulatory nod for a high-value oncology generic, moving the product into the final stages before potential commercialization.
Why it mattersOlaparib addresses a large $1.4 billion market; successful entry would provide a significant revenue stream to offset pricing pressures in Alembic's existing U.S. generic portfolio.
U.S. Market Size (IQVIA): $1.4 billionCumulative ANDA Approvals: 244Tentative Approvals: 20TTM Revenue: Rs 7111 Cr
📅 Short termThe news is sentimentally positive as it validates the R&D pipeline, but no immediate financial impact is expected until litigation concludes.
📈 Long termIf litigation is successful, this product could be a major contributor to Alembic's goal of launching 15-20 products annually in the U.S. market.
⚠ Risk flags
- Ongoing Para IV litigation
- Tentative status (not a final approval)
- Intense generic competition
Key Highlights
Target market size for Olaparib Tablets is approximately $1.4 billion in the U.S. for the year ending March 2026.
Alembic now holds a cumulative total of 244 ANDA approvals, consisting of 224 final and 20 tentative approvals.
The approval covers two dosage strengths: 100 mg and 150 mg tablets.
Alembic will act as the exclusive distributor for the product in the U.S. market once final approval is secured.
Para IV litigation is currently ongoing, which determines the eventual commercial launch timeline.
👀 What to Watch
Investors should monitor legal developments regarding the Para IV litigation, as a final approval and subsequent launch are contingent on a favorable court ruling or patent expiry.
USFDA Issues Warning Letter to Clinical Investigator at Vadodara Bioequivalence Facility
Alembic Pharmaceuticals has been notified of a USFDA Warning Letter dated July 10, 2026, issued to a Clinical Investigator at its Vadodara Bioequivalence Facility. The letter follows an inspection conducted from March 3 to March 7, 2025, and pertains to observations regarding Informed Consent Form (ICF) procedures. The company has clarified that the observations do not relate to data integrity and currently do not impose any operational restrictions on the facility. While no material financial impact is identified at this stage, the company is coordinating a response to the USFDA.
Confidence: HIGH
What changedA regulatory observation from a March 2025 inspection has escalated into a formal Warning Letter issued to a Clinical Investigator at the company's bioequivalence site.
Why it mattersWhile not a direct manufacturing ban, Warning Letters indicate regulatory friction. Since Alembic plans to launch 15-20 products in the US in FY26, any compliance issues at bioequivalence facilities could potentially delay the approval timeline for new generics.
Inspection Dates: 3rd March 2025 to 7th March 2025Warning Letter Date: 10th July 2026TTM Revenue: ₹ 7111 CrMarket Cap: ₹ 16365 Cr
📅 Short termThe stock may face minor sentiment pressure due to the 'Warning Letter' headline, though the lack of data integrity issues and operational restrictions provides some cushion.
📈 Long termIf the response is accepted by the USFDA without requiring re-conduct of studies, the long-term impact will be limited. Persistent regulatory issues, however, could impact the company's US growth strategy.
⚠ Risk flags
- Regulatory escalation
- Potential delays in product approvals
- Compliance risk at clinical study level
Key Highlights
Warning Letter dated July 10, 2026, issued to a Clinical Investigator associated with the facility.
Inspection conducted by USFDA over 5 days from March 3 to March 7, 2025.
Observations specifically relate to Informed Consent Form (ICF) and not to data integrity.
Company became aware of the communication on July 12, 2026.
No immediate operational restrictions or quantifiable financial impact reported.
👀 What to Watch
Investors should monitor the USFDA's response to the company's upcoming submission and check for any potential delays in ANDA approvals that rely on studies conducted at this facility.
Alembic Pharma Receives USFDA Final Approval for Dapsone Gel, 5%
Alembic Pharmaceuticals has received final USFDA approval for Dapsone Gel, 5%, a generic version of Almirall's Aczone Gel. The product is indicated for the topical treatment of acne vulgaris, expanding Alembic's dermatology portfolio in the US market. This approval brings the company's cumulative USFDA ANDA approvals to 244, demonstrating a consistent regulatory track record. The company continues to leverage its vertically integrated R&D to strengthen its generic product pipeline.
Key Highlights
Received final USFDA approval for Dapsone Gel, 5%, for treating acne vulgaris.
Product is therapeutically equivalent to the Reference Listed Drug (RLD) Aczone Gel, 5%.
Cumulative USFDA approvals now stand at 244, including 224 final and 20 tentative approvals.
Strengthens the company's presence in the US generic dermatology market.
👀 What to Watch
Investors should monitor the commercial launch and market share gains in the US dermatology segment. The consistent pace of ANDA approvals remains a positive indicator for long-term revenue growth in the US market.
Alembic Pharma Receives USFDA Approval for Oseltamivir Phosphate; $27M Market Size
Alembic Pharmaceuticals has received final USFDA approval for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, a generic version of Tamiflu. The product is indicated for the treatment and prophylaxis of influenza A and B in patients as young as 2 weeks. The addressable market for this suspension is estimated at US$ 27 million for the twelve months ending March 2026. This approval brings Alembic's cumulative USFDA ANDA approvals to 243, including 223 final approvals.
Key Highlights
Final USFDA approval received for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL.
Estimated market size of US$ 27 million for the 12-month period ending March 2026 per IQVIA.
Therapeutically equivalent to Hoffmann-La Roche's Tamiflu Oral Suspension.
Cumulative USFDA approvals reach 243, consisting of 223 final and 20 tentative approvals.
👀 What to Watch
Investors should view this as a positive step in Alembic's US generic expansion strategy. While the market size is relatively small, it demonstrates the company's consistent ability to secure regulatory approvals for its R&D pipeline.
Alembic Receives USFDA Tentative Approval for Binimetinib; Sole P-IV Filer for 45mg Strength
Alembic Pharmaceuticals has received tentative USFDA approval for Binimetinib Tablets (45 mg), used for treating metastatic melanoma and non-small cell lung cancer. Crucially, Alembic is the sole first applicant to file a Paragraph IV certification for this strength, potentially granting it 180 days of marketing exclusivity upon final approval. The market for this drug is estimated at US$ 259 million for the 12 months ending March 2026. This approval brings the company's total USFDA ANDA count to 242.
Key Highlights
Received USFDA tentative approval for Binimetinib Tablets, 45 mg, targeting a US$ 259 million market.
Identified as the sole first applicant with a Paragraph IV certification for the 45 mg strength.
Eligible for 180 days of generic marketing exclusivity in the US market upon final approval.
Cumulative USFDA ANDA approvals now stand at 242, including 222 final and 20 tentative approvals.
👀 What to Watch
Investors should view this as a significant regulatory milestone that could provide a high-margin revenue stream due to the 180-day exclusivity period; monitor for the timeline of final approval.
Alembic Pharma Receives USFDA Final Approval for Tretinoin Cream; Market Size $76 Million
Alembic Pharmaceuticals has received final USFDA approval for Tretinoin Cream USP, 0.05%, used for treating acne vulgaris. The product is a generic equivalent of Retin-A Cream and targets a US market size estimated at $76 million for the twelve months ending March 2026. This approval brings Alembic's cumulative total to 242 ANDA approvals, including 222 final approvals. This development strengthens the company's dermatological portfolio in the US market.
Key Highlights
Received USFDA final approval for Tretinoin Cream USP, 0.05%, indicated for acne vulgaris.
The product addresses an estimated annual market size of US$ 76 million according to IQVIA data.
The approved ANDA is therapeutically equivalent to the reference listed drug Retin-A Cream by Bausch Health.
Alembic now holds a cumulative total of 242 ANDA approvals (222 final and 20 tentative).
👀 What to Watch
Investors should monitor the company's product launch timeline and market share gains in the US generics space. This approval adds a steady revenue stream to the US business, which remains a key growth driver for Alembic.
CARE Reaffirms 'CARE A1+' Rating for Alembic Pharma's Rs 1,100 Cr Commercial Paper
CARE Ratings Limited has reaffirmed its 'CARE A1+' credit rating for Alembic Pharmaceuticals Limited's Commercial Paper program. The rating applies to a total facility amount of Rs 1,100.00 Crores as of June 11, 2026. This rating is the highest short-term credit rating possible, indicating a very strong degree of safety regarding timely payment of financial obligations. The reaffirmation suggests that the company maintains a stable financial profile and adequate liquidity to service its short-term debt.
Key Highlights
CARE Ratings Limited reaffirmed the 'CARE A1+' rating for the company's Commercial Paper.
The rating covers a total facility amount of Rs 1,100.00 Crores.
The 'A1+' rating signifies the highest degree of safety for short-term debt instruments.
The rating action was confirmed via a CARE Ratings press release dated June 11, 2026.
👀 What to Watch
Investors can remain confident in the company's short-term creditworthiness and liquidity position. No immediate portfolio changes are necessary as this is a reaffirmation of existing financial strength.
Alembic Pharma Receives USFDA Tentative Approval for Larotrectinib; Sole First-to-File Status
Alembic Pharmaceuticals has received tentative USFDA approval for Larotrectinib Capsules (25 mg and 100 mg), used for treating solid tumors. The company is the sole first applicant to file a Paragraph IV certification, which may grant it 180 days of generic marketing exclusivity in the U.S. upon final approval. The market size for this product is estimated at US$ 91 million for the twelve months ending March 2026. This milestone brings Alembic's total USFDA approvals to 241, including 20 tentative approvals.
Key Highlights
Received USFDA tentative approval for Larotrectinib Capsules (25 mg and 100 mg), a generic version of Vitrakvi.
Identified as the sole first applicant with a Paragraph IV certification, potentially securing 180 days of exclusivity.
Target market size for the product is approximately US$ 91 million as of March 2026.
Cumulative USFDA ANDA approvals reached 241, consisting of 221 final and 20 tentative approvals.
👀 What to Watch
Investors should monitor the transition from tentative to final approval, as the sole first-to-file status provides a significant competitive advantage and high-margin potential during the 180-day exclusivity period.
Alembic Pharma to Acquire 45% Stake in New Canadian JV for Market Expansion
Alembic Pharmaceuticals has executed a Shareholders' Agreement to invest in a newly incorporated Canadian entity, 17989377 Canada Inc. The company will hold a 45% equity stake, partnering with Difgen Holdings LLC (45%) to establish a platform for pharmaceutical commercialization in Canada. This move aims to strengthen Alembic's presence in the North American market through localized development, distribution, and marketing. Following the investment, the Canadian corporation will be classified as an associate company of Alembic.
Key Highlights
Acquisition of a 45% equity stake in the newly formed 17989377 Canada Inc.
Joint venture partnership with Difgen Holdings LLC (45%) and other parties (10%).
Strategic focus on development, marketing, and distribution of pharma products specifically for the Canadian market.
The Canadian entity will become an Associate company of Alembic Pharmaceuticals post-investment.
Governance structure includes nominee directors from shareholders and an independent director.
👀 What to Watch
This is a positive strategic step for geographic diversification; investors should track the joint venture's operational milestones and its eventual impact on the company's international revenue growth.
Alembic Pharma Receives USFDA Final Approval for Haloperidol Tablets; Market Size $27M
Alembic Pharmaceuticals has received final USFDA approval for its Haloperidol Tablets (1 mg, 2 mg, 5 mg, 10 mg, and 20 mg), a generic equivalent to Haldol. The drug is indicated for managing psychotic disorders and Tourette’s Disorder in both children and adults. The addressable market for this product is estimated at US$ 27 million for the twelve months ending March 2026. This approval further strengthens Alembic's US generics portfolio, bringing their total cumulative USFDA approvals to 240.
Key Highlights
Final USFDA approval received for Haloperidol Tablets in five different strengths (1 mg to 20 mg).
Product is therapeutically equivalent to the reference listed drug Haldol by Ortho McNeil Pharmaceutical.
Estimated market size for the product is US$ 27 million for the 12-month period ending March 2026.
Alembic now has a cumulative total of 240 ANDA approvals, including 221 final and 19 tentative approvals.
👀 What to Watch
Investors should monitor the company's ability to gain market share in this $27 million segment. While the market size is relatively small, the consistent pace of USFDA approvals reinforces Alembic's strong R&D and regulatory execution capabilities.
Alembic Pharma Appoints Tushar Mehta as Head-R&D (API); 24+ Years Experience
Alembic Pharmaceuticals has appointed Mr. Tushar Mehta as Head-R&D (API) effective June 3, 2026. Mr. Mehta brings over 24 years of specialized experience in API R&D, having previously led 100+ development programs with 45+ successful commercializations. His expertise spans complex therapeutic areas including oncology and antivirals, and he has a proven track record of managing large teams of up to 200 scientists. This strategic hire is aimed at strengthening the company's technical leadership and regulatory filing capabilities in the API segment.
Key Highlights
Mr. Tushar Mehta appointed as Head-R&D (API) and Senior Management Personnel effective June 3, 2026.
Brings 24+ years of experience, having led 100+ API development programs and commercialized over 45.
Expertise includes handling complex APIs like oncology, Remdesivir, and Molnupiravir, plus FDA/EMA regulatory filings.
Previously served as SVP & Head – R&D (API) at Cadila Pharmaceuticals and held leadership roles at Piramal and Ami Life Sciences.
Has experience directing large R&D teams of 200 scientists and filing multiple USDMFs.
👀 What to Watch
Investors should view this as a positive development for the company's long-term API pipeline and vertical integration strategy. Monitor for an increase in USDMF filings and complex API launches in the upcoming fiscal years.
